In view of the
rapidly developing
COVID-19 global pandemic, our
focus has been redirected to
this disease's pathology,
potential therapeutic targets
and treatment approaches.
Our publications in
this field and
COVID-19-related news are shown
below:
Chakraborty, P.,
Acharya, K.,
Sarkar, J.,
HABTEMARIAM, S.,
Sharifi-Rad, J.
Cho,W.C. (2024).
Antiviral
Activities of Naringenin
and Its Derivatives as
Adjuvant Treatmentagainst SARS-CoV-2
Infections.
In “Anti-SARS-CoV-2
Activity of
Flavonoids” CRC Press. eBook ISBN 9781003433200. 16 July
2024
Rezabakhsh,
A., Sadaie, M.R., Ala,
A.,
Roosta, Y.,
HABTEMARIAM, S.,
Sahebnasagh, A., Khezri,
M.R. (2024). STING
agonists as putative
adjuvants to boost
immunogenicity against
SARS-related infection:
The role of
autophagy. Cell
Communication and
Signaling 22,
305. FULL TEXTor PDF
Amini, S.,
Rezabakhsh, A.,
Hashemi, J., Saghafi,
F., Azizi, H., Sureda,
A., HABTEMARIAM, S.,
Khayat, Kashani, H.R,
Hesari, Z.,
Sahebnasagh, A. (2022)
Pharmacotherapy
consideration of
thrombolytic
medications in
COVID-19-associated
ARDS. J.
Intensive Care10(1),
38. FULL TEXT
Sureda, A.,
HABTEMARIAM, S.,
Nabavi, S.M. (2022).
The Pharmacology of
COVID-19. Chemico-Biological
Interaction 362,
110005. Abstrac
Nabavi,
S.M., Sureda, A.,
HABTEMARIAM, S. (2022).
SPECIAL
ISSUE
EDITION “The
Biochemistry and
Molecular Biology of
COVID-19”.
Chemico-Biological
Interaction -
IF-5.168.
See also "The
Pharmacology of
COVID-19. Chemico-Biological
Interaction 362,
110005."
Abstract
Other recent
additions:
Putative
therapeutic impact
of inflammasome
inhibitors against
COVID-19 driven
ARDS. Curr.
Med. Chem. Published
online on 6
September 2022.
Abstract
Pharmacotherapy
consideration of
thrombolytic
medications in
COVID-19-associated
ARDS. J.
Intensive Care
10(1), 38. FULL
TEXT
Cervical and
Preauricular
Lymphadenopathies as
Atypical
Manifestations in the
Setting of COVID-19: A
Case Report–
Future
Virology –
Published
on 11 February 2022
Efficacy
and safety of colchicine
treatment in patients
with COVID-19: A
prospective,
multi-center, randomized
clinical trial. Phytotherapy
Research
–
Published online on 2
February 2022
A
perspective on the
applications of furin
inhibitors for the
treatment of
SARS-CoV-2.Pharmacological
Reports
–
Published online on
15 January 2022
–
Anti-VEGF
Agents: As
Appealing Targets
in the Setting of
COVID-19 Treatment
in Critically Ill
Patients–
International
Immunopharmacology– Published
online on 16 October
2021
Can
we use mTOR Inhibitors
for COVID-19
Therapy?
– Combinatorial
Chemistry & High
Throughput Screening
– Published
on 30 November
2021.
Arglabin Could Target
Inflammasome-Induced
ARDS and Cytokine
Storm Associated with
COVID-19. Molecular
Biology Reports – Published
online on 15 October
2021
Systematic
Review:
Effectiveness of
Herbal Oral Care
Products on
Ventilator-Associated
Pneumonia. Phytotherapy
Research
(IF- 4.087)
– Published on
23 April 2021.
Efficacy
and Safety of
Levamisole Treatment
in Clinical
Presentations of
Non-Hospitalized
Patients with
COVID-19: a
Double-Blind,
Randomized, Controlled
Trial
– BMC
Infectious Diseases – Published
on 24 March 2021.
Rational
for effective
prophylaxis against
COVID-19 through
simultaneous
blockade of both
endosomal and
non-endosomal
SARS-CoV-2 entry
into host cell.
Clinical
and Translational
Science. Published
on 6 January 2021.
Drug
Development for the
Management of Corona
Viruses: Insights from
Natural Antiviral
Agents.Published
on 3 October 2020.
Coronavirus Vaccine News
of the Week - 22
September 2020
A
Review of
Medications Used to
Control and Improve
the Signs and
Symptoms of COVID-19
Patients - European
Journal of
Pharmacology -
Published Online
on 19 September
2020.
ØGlucose-6-Phosphate
Dehydrogenase
Deficiency and
SARS-CoV-2 Mortality:
Is there a Link…? – Clinical
Biochemistry –
Published online on
17 September 2020
From
the NewScientist -
Covid-19 news: WHO says
Europe can expect to see
a rise in deaths - 14
September 2020
The
Prophylaxis and
Treatment Potential
of Supplements for
COVID-19. European
Journal of
Pharmacology -
Published Online on
2 September 2020.
Pharmacological
Treatments of
COVID-19. Pharmacological
Reports
-
Published Online on
20 August 2020.
Various
Interferon
(IFN)-Inducible
Transmembrane
(IFITM) Proteins for
COVID-19, Is there a
Role for the
Combination of
Mycophenolic acid
and Interferon? Biochimie -
Available online on 14
August 2020.
Erythropoietin
as a Potential
Adjuvant Therapy for
Acute Lung
Injury/Acute
Respiratory Distress
Syndrome in Patients
with COVID-19Archives
of Medical Research.In Press -
Available online on 11
August 2020.
Possible
Targets and
Therapies of
SARS-CoV-2 Infection.Mini
Reviews in Medicinal
Chemistry. In
Press – Available
Online Ahead of
Print - 7 August
2020
Lessons
from SARS and MERS
Remind us of the
Possible Therapeutic
Effects of
Implementing a siRNA
Strategy to
Target
COVID-19:
Shoot the Messenger! Journal of
Cellular and
Molecular Medicine
- Available
online on 17
July 2020.
Should we
Try SARS-CoV-2
Helicase
Inhibitors for
COVID-19 Therapy? Archives of
Medical Research - Available
online on 31 May
2020.
May we
Target Double
Membrane Vesicles
and
Oxysterol-Binding
Protein to Combat
SARS-CoV-2
Infection? Cell
Biology
International-
Available online on
25 May 2020.
Neutrophil
Elastase Inhibitor
(Sivelestat), may be
a Promising
Therapeutic Option
for Management of
Acute Lung
Injury/Acute
Respiratory Distress
Syndrome or
Disseminated
Intravascular
Coagulation in
COVID-19. Preprint
available online via
Authorea on 18
May 2020. Journal of
Clinical Pharmacy
and Therapeutics.
Published online on
28 August 2020
Possible
use of the
mucolytic drug,
bromhexine
hydrochloride, as
a prophylactic
agent against
SARS-CoV-2
infection based on
its action on the
Transmembrane
Serine Protease 2.
Pharmacological
Research (IF 5.574)
-
4.
Available online: 30
April 2020
Should
we try the
anti-inflammatory
natural product,
celastrol, for
COVID-19?
Phytotherapy
Research - Published
Online: 29 April
2020.
SARS-CoV-2
infection, COVID-19 and
other coronavirus
diseases.. Visit our
new Special Issue for
article contribution.
COVID-19,
Chloroquine
Repurposing, and
Cardiac Safety
Concern: Chirality
Might Help. If they have
efficacy against
COVID-19, this could
be what we need to do
improve their safety
and efficacy ... Molecules - 16
April 2020
Lessons
learned from
SARS-CoV and
MERS-CoV:
FDA-approved Abelson
tyrosine-protein
kinase 2 inhibitors
may help us to
combat SARS-CoV-2.
Archives
of Medical Science -
Published on 14 April
2020.
4.
Repurposing
Therapeutic Agents and
Herbal Medicines to
Defeat Viral Nemesis. Drug Development
Research- Published on 30
March 2020.
Other
Publications on Our
Antiviral Activity
Studies
See our
article on
antiviral
activity of
Tansy: Álvarez, Á.L, HABTEMARIAM, S,
Juan-Badaturuge,
M, Jackson,
C, Parra,
F.
(2011).
In vitro
anti HSV-1 and
HSV-2 activity
of
Tanacetum
vulgare
extracts and
isolated
compounds: An
approach to
their
mechanisms of
action.
Phytotherapy
Research.
25(2),
296-301.
Abstract
...See
an overview of
our Research
on Tansy...
Álvarez, Á.L.,
HABTEMARIAM, S., Dalton,
K.P., Nicieza, I.,
Parra, F. (2015. A spiroketal-enol
ether derivative from Tanacetum
vulgare
selectively inhibits
HSV-1 and HSV-2
glycoprotein
accumulation in Vero
cells. Antiviral
Research 119, 8-18. Abstract
....
and visit our publications' page for more references.
Dr
Habtemariam BSc, MSc, PhD,
PGDipMS, FRSC, … As a
world-class scientist in the field
of natural products’ chemistry
(phytochemistry) and pharmacology/
pharmacognosy, he is an author of
over 300 research papers
in top-tier journals
and several books. His research
covers a broad area of drug
discovery from natural sources,
modernisation of herbal medicines,
and the science of medicinal
foods and nutraceuticals ... More
Expertise
Dr
Habtemariam’s expertise is based on
decades of research &
consultancy on pharmacological assay
development in vitro, in
vivo and clinical studies. His
work on qualitative and quantitative
analysis of medicinal products,
separation/isolation of active
ingredients, and structural
elucidations of natural products
have been based on state-of-the-art
equipment including HPLC
systems, NMR, mass
spectrometry, etc... More
Dr
Habtemariam is actively
engaged on research and
outreach activities on topical
issues of the UK higher education
system. This includes critical
analysis of institutional culture,
quality assurance on teaching &
research … policy shift and emerging
trends from the global higher
education market perspective. Some
of the articles and discussion
topics are
published in the news media as
well as his own conversation forum -
The HAS Seminar Series.